Pioneer Surgical receives patent for nanOss technology

Pioneer Surgical Technology, Inc., a global medical device provider in orthopaedics, spine, and biologics, is proud to announce the United States Patent Office has reissued a patent further strengthening Pioneer's market position in nanocrystalline derived products used in orthopaedics.

The patent supports Pioneer Surgical's nanocrystalline calcium phosphate technology – nanOss™.  Mr. Shane Ray, General Manager- Biologics stated, "This patent issuance is a great achievement with our license with Massachusetts Institute of Technology (M.I.T.) and Pioneer's biologic research and development team.  Throughout recent history medical device and biologic companies have attempted to create synthetic bone.  With the advances from Pioneer's team and through the addition of the first FDA cleared product utilizing nanocrystalline materials in orthopaedics, we feel we have created the closest technology to human bone available to patients today."  

Pioneer's first developed biologic product, nanOss Bioactive was launched in the United States in 2009 and is a bone void filler/bone graft substitute used in orthopaedics.  

For more information regarding nanOss Bioactive, please visit the Pioneer Surgical website at www.pioneersurgical.com.

SOURCE Pioneer Surgical Technology, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Aptamer extends agreement with genetic medicines customer